학술논문
Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS)
Document Type
Report
Author
Source
Journal of Comparative Effectiveness Research. January 2015, Vol. 4 Issue 1, p3, 7 p.
Subject
Language
English
ISSN
2042-6305
Abstract
Author(s): Ronald C Chen [sup.[*]] [sup.aff1] [sup.aff2] [sup.aff3] , William R Carpenter [sup.aff2] [sup.aff4] , Mimi Kim [sup.aff1] , Laura H Hendrix [sup.aff2] [sup.aff3] , Robert P Agans [sup.aff5] , [...]
The North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS) was designed in collaboration with stakeholders to compare the effectiveness of different treatment options for localized prostate cancer. Using the Rapid Case Ascertainment system of the North Carolina Central Cancer Registry, 1,419 patients (57% of eligible) with newly-diagnosed localized prostate cancer were enrolled from January 2011 to June 2013, on average 5 weeks after diagnosis. All participants were enrolled prior to treatment and this population-based cohort is sociodemographically diverse. Prospective follow-up continues to collect data on treatments received, disease control, survival and patient-reported outcomes. This study highlights several important considerations regarding stakeholder involvement, study design and generalizability regarding comparative effectiveness research in prostate cancer.
The North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS) was designed in collaboration with stakeholders to compare the effectiveness of different treatment options for localized prostate cancer. Using the Rapid Case Ascertainment system of the North Carolina Central Cancer Registry, 1,419 patients (57% of eligible) with newly-diagnosed localized prostate cancer were enrolled from January 2011 to June 2013, on average 5 weeks after diagnosis. All participants were enrolled prior to treatment and this population-based cohort is sociodemographically diverse. Prospective follow-up continues to collect data on treatments received, disease control, survival and patient-reported outcomes. This study highlights several important considerations regarding stakeholder involvement, study design and generalizability regarding comparative effectiveness research in prostate cancer.